News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1234
5
678910
found Documents: 481
London: Tuesday, November 1, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the
Read More
Shanghai agreement triggers a one-time gain to Chi-Med of US$38.2 million in Q4 2016 Shanghai factory relocation complete: now operational with three-fold increase in capacity Cash from Chi-Med Commercial Platform supports developmen
Read More
London: Wednesday, October 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (
Read More
London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US
Read More
London: Tuesday, August 2, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who ha
Read More
Group revenue up 27% to $104.5 million (H1 2015: $82.5m) and net income attributable to Chi‑Med of $0.5 million (H1 2015: $15.9m), reflecting a sharp increase in clinical investment.   Innovation Platform – Seven drug candidates in 25
Read More
First global pivotal Phase III in c-Met-driven papillary renal cell carcinoma (“PRCC”) to be initiated in the near future London: Monday, August 1, 2016: Chi-Med and AstraZeneca today announced an amendment (the “Amendment”) to the 2011 glo
Read More
London: Tuesday, July 5, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2016 on Tuesday, August 2, 2016 at 7:00 am British Summer Time (BST). An a
Read More
Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study builds on encouraging data from initial small Phase II studies of savolitinib in combination with Tagrisso or Iressa in c-Met-am
Read More
London: Wednesday, June 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,000,000 ordinary shares, par value of U
Read More
London: Tuesday, May 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2016, the issued share capital of Chi-Med consisted of 60,649,342 ordinary sha
Read More
London: Friday, May 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced
Read More
London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary
Read More
London: Wednesday, April 27, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting ("AGM") held on April 27, 2016 were duly pas
Read More
London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have
Read More
London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli
Read More
London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary
Read More
London: Tuesday, March 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Deposi
Read More
  For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying is
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represen
Read More
London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONS
Read More
Press Release London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app
Read More
London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
Press Release London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
London: Wednesday, 2 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated an open-label Phase II clinical trial to evaluate t
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III
Read More
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Read More
London: Friday, 29 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) will be announcing its final results for the year ended 31 December 2015 on Tuesday, 1 March 2016.  An analyst presentation will be held at 9:00 am on the
Read More
London: Friday, 15 January 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated a Phase I trial in Australia in patients with haema
Read More
London: Tuesday, 29 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limited   2. Name of scheme: Hutc
Read More
London: Friday, 18 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) regist
Read More
Press Release London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
Read More
London: Tuesday, 8 December 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated FALUCA, a Phase III registration study for fruqu
Read More
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF. --- NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Read More
London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were
Read More
London: Monday, 9 November 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) hereby makes the following amendments to the "Director's Share Dealing" announcement released on 20 October 2015 subsequent to the notification received from Mr
Read More
London: Friday, 6 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012
Read More
 Press Release London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
Read More
London: Friday, 30 October 2015: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) hereby notifies the market that as at 30 October 2015, the issued share capital of Chi-Med consisted of 56,533,118 ordinary shares
Read More
London:  Friday, 30 October 2015:  Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has successfully completed its first-in-human Phase I clini
Read More
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
Read More
London: Tuesday, 20 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) received notification on 19 October 2015 that Mr Christopher Nash, Independent Non-executive Director, has: purchased jointly with his spouse 4,512 ordi
Read More
London: Monday, 19 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that the Remuneration Committee of Chi-Med today granted conditional awards (the “LTIP Awards”) under the Long Term Incentive Plan (the “LTIP
Read More